Update Presented for PROGRESS-CTO International Registry
April 30, 2018—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that a significant update to the PROGRESS-CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) international registry was presented at the 2018 SCAI scientific sessions, held April 25–28 in San Diego, California.
According to SCAI, the presentation outlined contemporary outcomes of chronic total occlusion percutaneous coronary intervention (CTO PCI) by analyzing the clinical, angiographic, and procedural characteristics of 3,122 CTO interventions performed in 3,055 patients at 20 centers in the United States (17), Europe (2) and Russia (1). The new data are representative of contemporary practice and outcomes.
The investigators analyzed success rates of antegrade wire escalation, antegrade dissection and re-entry, and the retrograde approach for CTO interventions.
The mean age of the patients was 65 ± 10 years and 85% of the patients were men, with high prevalence of diabetes (43%), previous myocardial infarction (MI; 46%), previous coronary artery bypass graft surgery (33%), and previous PCI (65%).
The overall technical and procedural success rates were 87% and 85%, respectively. The rate of in-hospital major complications was 3% (composite of death [0.9%], acute MI [1.1%], stroke [0.3%], tamponade [0.9%], emergency surgery [0.2%], and re-PCI [0.4%]). The success rates for the antegrade wire escalation, antegrade dissection and re-entry, and retrograde approach were 87.3%, 89.7%, and 83%, respectively.
In the SCAI announcement, Peter Tajti, MD, commented, "The high success and acceptable complication rates suggest that at experienced centers CTO PCI can provide significant clinical benefits to the patients. The study results can facilitate discussions with both patients and physicians about the risk to benefits of the procedure and guide decision making on CTO PCI.”
The investigators are working on a new, multicenter study that includes centers from around the world to further assess the effect of CTO PCI symptoms when compared to the placebo-controlled procedure, noted SCAI.